文献速递核素与放射性配体治疗放射性药物与辐射防护

转移性前列腺癌伴基线轻中度白细胞减少患者对PSMA放射性配体治疗的耐受性

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia.
PubMed 文献 · EJNMMI Res · 2025-07-06

本研究纳入37例存在白细胞减少(白细胞计数<3.8×10^9/L)的转移性去势抵抗性前列腺癌(mCRPC)患者,接受中位3周期[177Lu]Lu-PSMA-617治疗。各周期及治疗结束时白细胞计数与基线相比无显著差异,27%患者CTCAE评分稳定、46%升高、27%降低。作者认为PSMA-RLT在CTCAE≥1级白细胞减少患者中可行,不应将白细胞减少患者一概排除。

要点

  • 37例mCRPC伴白细胞减少患者接受中位3周期[177Lu]Lu-PSMA-617治疗。
  • 各周期后白细胞计数与基线相比无显著差异(p均>0.05)。
  • 治疗结束时27%患者CTCAE评分稳定、46%升高、27%降低。

核心结论

  • 作者认为PSMA-RLT在CTCAE≥1级白细胞减少患者中可行,白细胞计数保持稳定且无显著RLT诱导的恶化。
  • 作者认为不应将白细胞减少患者一概排除在PSMA-RLT之外。

研究设计与样本

  • 本研究为单臂研究,纳入37例存在白细胞减少(白细胞计数<3.8×10^9/L)的mCRPC患者。
  • 患者接受中位3周期[177Lu]Lu-PSMA-617治疗(范围1-9周期)。
  • 试验注册号:Clinicaltrials.gov NCT04833517,注册日期2016年1月1日。

主要发现

  • 第一周期后白细胞计数基线3.0±0.5 vs 随访3.4±1.4(×10^9/L),p=0.0921,无显著差异。
  • 第二周期后白细胞计数基线3.1±0.4 vs 随访3.8±1.7,p=0.0509,无显著差异。
  • 第三周期后白细胞计数基线3.1±0.4 vs 随访3.2±2.0,p=0.2929,无显著差异。
  • 治疗结束时(不论周期数)白细胞计数基线3.0±0.5 vs 结束3.5±1.4,p=0.0684,无显著差异。
  • 治疗结束后CTCAE评分:27%患者稳定,46%升高,27%降低。

临床怎么用

  • 作者认为PSMA-RLT在CTCAE≥1级白细胞减少的mCRPC患者中可行。
  • 作者认为不应将白细胞减少患者一概排除在PSMA-RLT之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1). RESULTS: Thirty-seven mCRPC patients with preexisting leukopenia (leukocyte count < 3.8 × 109/L) were included in this study. Patients received a median of 3 cycles of [177Lu]Lu-PSMA-617 (range 1-9). No significant difference in leukocyte counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (3.0 ± 0.5 at baseline vs. 3.4 ± 1.4 at follow up [in × 109/L], p = 0.0921), second cycle (3.1 ± 0.4 vs. 3.8 ± 1.7, p = 0. 0.0509), and third cycle (3.1 ± 0.4 vs. 3.2 ± 2.0, p = 0.2929), respectively. Similarly, baseline and end of treatment values, irrespective of the number of administered cycles, did not reveal a significant difference (3.0 ± 0.5 vs. 3.5 ± 1.4, p = 0.0684). After the end of therapy, irrespective of the number of administered cycles, 27% patients remained stable in terms of CTCAE scoring, 46% changed to a higher score and 27% improved to a lower score. CONCLUSION: Although marked preexisting leukopenia is often considered a relative contraindication for PSMA-RLT, our findings indicate that PSMA-RLT is feasible in patients with leukopenia of CTCAE grade ≥ 1. In our cohort, leukocyte counts remained stable without significant RLT-induced deterioration. Therefore, patients with leukopenia should not be categorically excluded from receiving PSMA-RLT. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04833517, registered 01.01.2016.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Bastian MB, Speicher T, Blickle A, et al. Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia. EJNMMI Res. 2025. PMID: 40619537. doi:10.1186/s13550-025-01280-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。